Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biotechnology innovator developing intranasal immunotherapies for neurodegenerative and inflammatory diseases. This page provides centralized access to official corporate announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on TLSA's novel drug delivery platform, including progress with intranasal foralumab and other candidates targeting multiple sclerosis, Alzheimer's, and autoimmune conditions. The repository includes press releases on FDA communications, partnership announcements, and peer-reviewed research findings.
Key content categories include clinical trial milestones, intellectual property updates, executive leadership changes, and financial performance reports. All materials are sourced directly from the company and verified financial news outlets to ensure accuracy.
Bookmark this page for streamlined tracking of TLSA's progress in advancing non-invasive immunotherapy solutions. Check regularly for updates on groundbreaking approaches to modulating immune responses through nasal administration.
Tiziana Life Sciences (NASDAQ: TLSA) announced positive results from its Phase 1 trial of nasally administered Foralumab, showing significant immunomodulatory effects. Conducted at Brigham and Women’s Hospital, the study demonstrated that a 50 mcg/day dose led to favorable changes in cytotoxic T-cell subsets and inflammatory biomarkers without severe toxicity. These findings support further clinical development, primarily targeting progressive MS. Tiziana's innovative approach may enhance treatment outcomes for neurodegenerative diseases.
Tiziana Life Sciences (NASDAQ: TLSA) announced the dosing of the first patient with secondary progressive multiple sclerosis (SPMS) with nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody. The study, conducted at Brigham and Women’s Hospital, focuses on evaluating the treatment's safety, tolerability, and neurological responses over six months. Previous studies indicated Foralumab's well-tolerated nature and strong anti-inflammatory effects, with results showing no significant adverse events. The trial aims to address the urgent need for effective SPMS treatments.
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) announces an interview with CEO Dr. Kunwar Shailubhai, set to air on The RedChip Money Report on May 8, 2021, at 7 p.m. local time. The program reaches approximately 73 million homes via Bloomberg Television. Tiziana focuses on novel therapies in oncology and immunology, with key developments including Foralumab, a unique anti-CD3 monoclonal antibody, and an anti-IL6R monoclonal antibody targeting COVID-19 related inflammation. Caution is advised regarding forward-looking statements.
Tiziana Life Sciences (TLSA) announced a partnership with Takanawa Japan K.K. to find a clinical partner for Milciclib, aimed at treating advanced hepatocellular carcinoma (HCC) in Asia. Milciclib has shown positive results in phase 1 and phase 2 trials, demonstrating tolerability in sorafenib-resistant patients. The partnership focuses on addressing the high prevalence of HCC in Asian countries where treatment options are limited. A recent patent was granted for Milciclib's use in combination therapies, enhancing its development prospects.
Tiziana Life Sciences announced that its CEO Dr. Kunwar Shailubhai and Dr. Howard Weiner will participate in a fireside chat on April 28, 2021, at 10:30 a.m. EDT. The video link session will provide updates on the company's progress, focusing on its innovative therapeutics for oncology and inflammation. Topics will include development efforts for Foralumab and anti-IL6R monoclonal antibodies. No new information will be shared, only data already available publicly. Tiziana is known for its work in treating autoimmune and inflammatory diseases.
On April 13, 2021, Tiziana Life Sciences plc (NASDAQ:TLSA) announced plans for its former subsidiary, Accustem Sciences, to apply for a Nasdaq listing following the distribution of shares to Tiziana's shareholders. The board believes this move aligns better with Accustem's business. Accustem's StemPrintER assay predicts the recurrence risk in R+/HER2- breast cancer patients and has shown superior prognostic capabilities over Oncotype DX. This test aims to refine treatment approaches, helping to identify patients at heightened risk for metastasis.
Tiziana Life Sciences (NASDAQ: TLSA) announced the FDA's approval for evaluating nasal administration of Foralumab in a secondary progressive multiple sclerosis (SPMS) patient at Brigham and Women's Hospital. This marks the first nasal delivery of an antibody for SPMS. The treatment is set to commence in Q2 2021. Prior Phase 1 trials indicated Foralumab's safety for nasal administration. The company aims to address the urgent need for effective treatments in SPMS and has previously reported positive data from COVID-19 studies in Brazil.
Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) has filed a Form 20-F with the SEC to finalize the distribution of shares in Accustem Sciences Limited to its shareholders in the US through the ADS program. This move will separate Accustem as an independent entity, allowing it to pursue its own listing. Shareholders can access detailed information about Accustem via the SEC report linked in the press release.
Tiziana Life Sciences (NASDAQ: TLSA) announced plans for a phase 2 clinical trial of Foralumab, a nasally administered anti-CD3 monoclonal antibody targeting Covid-19. Previous studies indicated Foralumab reduced lung inflammation in mild to moderate cases. The new trial will focus on hospitalized patients in Brazil and aims to validate Foralumab's effectiveness and safety as a nasal immunomodulatory therapy. This innovative approach leverages Foralumab's unique nasal delivery system to potentially alleviate severe Covid-19 symptoms, irrespective of viral variants.
Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) has announced that its Chairman, Gabriele Cerrone, will appear on Bloomberg Television on March 30, 2021, at 1:50 PM US Eastern Time. This update corrects the previously announced schedule. Tiziana focuses on developing innovative therapies for oncology and inflammation, including Milciclib and Foralumab, the latter being a fully human anti-CD3 monoclonal antibody for various autoimmune and inflammatory diseases. The company is also advancing an anti-IL6R monoclonal antibody for treating COVID-19 related inflammation.
FAQ
What is the current stock price of Tiziana Life Sciences Com (TLSA)?
What is the market cap of Tiziana Life Sciences Com (TLSA)?
